This was created to support the use of PADnet in the Medicare Advantage space by screening all diabetic patients for peripheral artery disease

1. Boost more diabetic
patients from HCC 19
to HCC 18
Example Expenses
Paid to provider/member tested $150
Members tested 750
Total cost of testing $112,500
Net Profit Total $ $630,000
Example RAF Lift
Total Population Size with Diabetes 1,000
% of Population Assessed w/PADnet 75%
# of PADnet studies 750
% of Positive PAD Detection 33%
# of PAD Positive Members Detected 248
Medicare Advantage rate pm/pm $1,000
RAF Boost for HCC 18 0.25
Per Member/Per Year Boost $3,000
Durable annual RAF lift $742,500
Sample Scenario:
Assessing all
diabetic patients
for PAD with
PADnet
Peripheral vascular disease, including peripheral artery
disease (PAD), is a factor that is widespread throughout
Medicare Advantage population, particularly those with
diabetes.
Each PADnet includes the Biomedix mobile health
assessment platform. Diagnostic data is transmitted and
stored in a HIPAA-compliant cloud. This platform is able to
accommodate a wide variety of health assessment models
so that interventionalists can access data for remote
interpretation, and disease management coordinators can
collect and analyze data from other diagnostic devices.
3x
Uses cuff-based technology, making it less
technician-dependent and easier to use than
Doppler- and ABI-based diagnostic devices
Diagnoses venous disease, a factor which affects
3x more Americans than arterial disease
Identifies peripheral artery disease, a factor
affecting 1 in 3 patients aged 50+ with
diabetes
Vascular Assessment System
PADnet
®
Mobile Health Assessment Platform
biomedix
®
©2017 Biomedix dba Collaborative Care Diagnostics, LLC • PADnet is a registered trademark of Biomedix • ML-212 Rev A Feb 2017
PADNET: U.S. PATENTS 7,983,930; 8,229,762 B2; 7,214,192; 7,172,555; 7,166,076 & PATENTS PENDING.
ï biomedix.com
% sales@biomedix.com
! (877) 854-0014